Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. to Present at the 28th Annual ROTH Conference
Mar 11, 2016
PDF 12.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update
Mar 7, 2016
PDF 295.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at Upcoming Investment Conferences
Mar 7, 2016
PDF 13.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2015 Financial Results and Business Update
Mar 4, 2016
PDF 13.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TGR-1202 in the United States
Feb 23, 2016
PDF 16.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 18th Annual BIO CEO & Investor Conference
Feb 3, 2016
PDF 12.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Sets Corporate Goals and Objectives for 2016
Jan 19, 2016
PDF 18.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 11, 2016
PDF 12.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University at the 57th American Society of Hematology Annual Meeting
Dec 7, 2015
PDF 18.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations for TGR-1202 and TG-1101 in Combination With Ibrutinib at the 57th American Society of Hematology Annual Meeting
Dec 7, 2015
PDF 92.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the 57th American Society of Hematology Annual Meeting From Ongoing Clinical Studies in Patients With Non-Hodgkins Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Dec 6, 2015
PDF 24.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 57th American Society of Hematology Annual Meeting
Dec 4, 2015
PDF 19.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update
Nov 9, 2015
PDF 119.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 57th American Society of Hematology Annual Meeting
Nov 5, 2015
PDF 20.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2015 Financial Results and Business Update
Nov 4, 2015
PDF 11.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2015 Healthcare Conference
Sep 25, 2015
PDF 13.9 KB Add to Briefcase
View Summary TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 (ublituximab) in Combination With TGR-1202 for Patients With Chronic Lymphocytic Leukemia (CLL)
Sep 17, 2015
PDF 112.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) at the University of Pennsylvania's Abramson Cancer Center
Sep 9, 2015
PDF 111.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Participate in Upcoming Investment Conferences in September
Sep 8, 2015
PDF 14.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results and Business Update
Aug 10, 2015
PDF 119.5 KB Add to Briefcase
Showing 61-80 of 183 Page: 1 2 3 4 5 6 7 8 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase